To NASDAQ OMX Copenhagen A/S
Announcement no. 10-13 / Copenhagen, April 10, 2013
Topotarget A/S today held its annual general meeting at Symbion, Fruebjergvej 3, 2100 Copenhagen, Denmark.
At the meeting, Chairman of the board, Bo Jesper Hansen, and Chief Executive Officer, Anders Vadsholt, gave a report on the company's activities during the past year. The audited annual report was adopted and a resolution was passed to discharge the Board of Directors and the management from liability. It was resolved that the loss for the year of DKK 80 million be carried forward to next year through recognition in retained earnings.
Bo Jesper Hansen, Anker Lundemose, Ingelise Saunders, Jeffrey H. Buchalter, Per Samuelsson, Gisela Schwab, and Karsten Witt were re-elected for a period of one year. Deloitte, Statsautoriseret Revisionsaktieselskab was re-appointed as the company's auditors.
The proposals by the Board of Directors to change Article 6(e) (extension and increase of authorization to the board of directors to issue warrants) and Article 7 (extension and increase of authorization to the board of directors to increase the share capital) of the Articles of Association, were both adopted.
The Board of Directors was authorized to purchase treasury shares within a limit of 10% of the company’s share capital at a price corresponding to the listed price plus/less 5% at the time of the purchase. The Chairman of the meeting was authorized to apply for registration of the resolutions passed and to make any such amendments thereto as may be required by the Danish Business Authority as a condition for registration or approval.
Immediately after the general meeting the Board of Directors convened and elected Bo Jesper Hansen as Chairman.
For further information, please contact:
Topotarget A/S
Anders Vadsholt, CEO: Direct: +45 39178345
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is an international biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.
